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Respiratory syncytial virus (RSV) is the major cause for respiratory tract disease in infants and young chil-
dren. Currently, no licensed vaccine or a selective antiviral drug against RSV infections are available. Here,
we describe a structure-based drug design approach that led to the synthesis of a novel series of zinc-
ejecting compounds active against RSV replication. 30 compounds, sharing a common dithiocarbamate
moiety, were designed and prepared to target the zinc finger motif of the M2-1 protein. A library of
12,000 small fragments was docked to explore the area surrounding the zinc ion. Among these, seven
ligands were selected and used for the preparation of the new derivatives. The results reported here may
help the development of a lead compound for the treatment of RSV infections.
 2015 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Respiratory syncytial virus (RSV) is considered as the major
cause of acute lower respiratory tract infections (ALRIs) in infants
and children, causing the majority of hospitalization of young peo-
ple ranging from ages 1 to 5 years old (Hall et al., 2009; RSV). The
virus is highly contagious and re-infection occurs frequently with a
risk of morbidity in elderly people with chronic illnesses and
immunocompromised patients and a mortality rate between 3%
and 9% in infants (Nokes et al., 2010; Falsey et al., 2005). Despite
the huge economic impact and the medical needs associated with
severe RSV infection, no vaccine nor a specific antiviral therapy are
available at the moment. Currently, only supportive treatments
and prophylaxis with Palivizumab are at hands (Wainwright,
2010). While many efforts are focused on the development of a safe
RSV vaccine, designing antiviral drugs targeting viral proteins rep-
resent a valuable alternative (Mackman et al., 2015; Wang et al.,
2015).
RSV is an enveloped, single-stranded, negative RNA virus
belonging to the Paramyoxiviridae family (Easton and Pringle,
2011). Its genome encodes 11 proteins, and among these the M2-
1 protein is an essential transcription antitermination cofactor of
the viral RNA-dependent RNA polymerase (RdRP) complex of
which the crystal structure has been recently released (PDB code:43CB) Tanner et al., 2014. This protein increases the polymerase
function and prevents the termination of the transcription event,
which is an essential event for the synthesis of full-length mRNA
(Collins et al., 1996) and for the synthesis of polycistronic read-
through mRNAs (Sutherland et al., 2001; Fearns and Collins,
1999; Hardy and Wertz, 1998). M2-1 contains a zinc binding
domain (ZBD) that is situated at the N-terminus of the protein. It
has been demonstrated that its integrity is a key element for main-
taining the functional integrity of the M2-1 (Hardy and Wertz,
2000). Mutants of some of the residues that are coordinated with
the zinc ion alter the activity of the protein by reducing the tran-
scription event, changing the phosphorylation state of the protein
and preventing interactions between M2-1 and the nucleocapsid
protein (Collins et al., 1996; Sutherland et al., 2001; Fearns and
Collins, 1999; Hardy and Wertz, 1998, 2000; Tang et al., 2001).
The sequence of the zinc finger motif (C-X7-C-X5-C-X3-H) slightly
differs from other ZBDs, e.g. the one in the nucleocapsid (NC)
protein of the human immunodeficiency virus 1 (HIV-1).
Nevertheless, Zn2+ ion is linked to the Cys3-His1 motif in a similar
way as its binds the zinc domain of HIV-1 by coordinating three
cysteine and one histidine residues (Fig. 1) Berg, 1986;
Henderson et al., 1981.
Zinc ejection has been already described in the literature as a
method of enzyme inhibition (Rice et al., 1993). A successful exam-
ple of metal chelation by zinc-ejecting compounds is represented
by the effect of azodicarbonamides on the HIV nucleocapsid
(NCp7) that selectively eject zinc ions (Loo et al., 1996; Rice
Fig. 1. RSV zinc binding domain: Cys3-His1 coordinated zinc atoms are shown in
green with the N-terminal face of the core of an adjacent monomer represented in
blue (PDB code: 43CB). (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
Fig. 2. Representation of several fragments docked in the zinc binding site.
Fragments are differently colored according to the targeted area: the pale blue
ones are docked in the upper area, the orange ones in the lower region (above).
Chemical scaffold of the new aryl carbodithiolates (below). (For interpretation of
the references to color in this figure legend, the reader is referred to the web version
of this article.)
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these NCp7 zinc-ejecting compounds is currently in phase I/II clin-
ical trials to evaluate its potential to treat advanced acquired
immunodeficiency disease syndrome (AIDS) Vandevelde et al.,
1996. Based on the common function and geometry of the zinc fin-
ger motif between Retroviruses and RSV, a recent study evaluated
the effect of 2,20-dithiopyridine (aldrithiol, AT-2), known to inacti-
vate HIV-1 by modifying the NC zinc finger, on the RSV infectivity.
The results showed the ability of this molecule to inactivate RSV at
a concentration of 10 mM, presumably by modification of the M2-1
protein (Boukhvalova et al., 2010). Considering these data, we used
a structure-based drug design approach to generate a series of
compounds containing a zinc-chelating moiety. In this study, we
initially docked a number of fragments into the targeted area to
evaluate their potential interactions around the zinc atom.
Selected fragments were then linked to the dithiocarbamate group,
which is known to have zinc ejecting properties (Thorn and
Ludwig, 1962). Furthermore, this group has also been reported as
an essential feature for the antiviral activity of pyrrolidine dithio-
carbamate (PDTC) in several RNA viruses (Lanke et al., 2007),
therefore it was chosen as the core feature for our compounds.
Based on the initial results, different series of new potential zinc-
ejecting compounds were synthesised and tested for their antiviral
activity in cell-based RSV infection assays.
2. Materials and methods
Detailed molecular modeling and chemical procedures are
reported in the Supplemental information file.
3. Results and discussion
3.1. Computer-aided design
The ZBD of M2-1 protein is a very tight binding pocket, defined
by three cysteine residues and a histidine that have a simple geom-
etry and form a planar ring which surrounds the Zn ion. Due to the
small size of the region, our approach was to use a library of small
fragments instead of traditional screening libraries that tend to be
constituted by a variety of large and lipophilic molecules that could
not fit the binding area. On the other hand, generating hits usinglibraries of smaller dimensions increase the chance of observing
favorable interactions. The ZINC database is a collection of com-
mercially available chemical compounds organized into different
subsets of molecules filtered according to various parameters
(Irwin et al., 2012). The ‘clean fragments’ subset, which is com-
posed of 1,611,889 small molecules, was downloaded and used
in this study. In this database, aldehydes and thiols are not present,
the compounds have a logP less or equal to 3.5, a molecular weight
less than 250 and rotatable bonds equal or less than 5. We further
filtered the database by molecular weight: only those fragments
with a molecular weight less than 150 were taken into account
for docking studies. A total of 12,420 ligands were then docked
in the proximity of the zinc binding domain. A series of docking
simulations using MOE (Molecular Operating Environment, version
2009.10, Chemical Computing Group Inc.) was carried out to assess
which fragments could best fit two different pocket subsites, in
particular the areas that are in close proximity to the Cys3-His1
motif: a first region defined by Gly18, Lys19, His22, Ser24 and
His25 (Fig. 2) and a second area defined by Glu10, His14 and
Cys15. After evaluating their binding scores and interactions by a
visual inspection of the generated poses, the original input data-
base was reduced to 100 fragments, of which seven were selected
according to the synthetic feasibility of the corresponding com-
pounds. A general unsymmetrical three-membered scaffold was
designed to contain a common central dithiocarbamate linker,
functionalized on its two sides with different moieties that were
further validated by another set of docking studies (Fig. 2).
Fig. 3. Predicted binding mode of compound 10e.
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tion to target residues Glu10, His14, a central part formed by the
dithiocarbamate moiety that occupies the area around the zinc
atom and an alicyclic amine that resides in the region defined by
residues Gly18, Lys19 Cys21, His22, Ser24 and His25. Six aromatic
fragments were chosen, corresponding to 2-chloromethyl ben-
zoimidazole, 2-chloromethyl benzothiazole, 2-chloromethyl ben-
zoxazole, 4-(trifluoromethyl)benzyl bromide, 3-nitrobenzyl
bromide and 4-bromomethyl-3-nitrobenzoic acid. For the alicyclic
amines, piperidine, morpholine, N-methyl piperazine, piperazine
and benzyl piperazine were chosen. All the designed compounds
were docked in the targeted area using PLANTS (version 1.1) soft-
ware package (Korb et al., 2009) and they all nicely fit into the
selected binding region. The predicted binding mode for compound
10e is shown in Fig. 3 as a representative example. From these
results, it is possible to see how 10e establishes a stacking interac-
tions with the imidazole ring of His14 through the benzoxazole
ring, while the N(C@S)AS group is in close proximity to the Zn
ion. Furthermore, the benzyl piperazine moiety establishes
hydrophobic interactions with Lys19.NH
X
1a-e
a: X = CH2
b: X = O
c: X = NMe
d: X = NH
e: X = C6H5CH2
+
Ar Cl
or
Ar Br
2,3
4-8
  2,9: Ar = 2-benzoimidazo
3,10: Ar = 2-benzothiazole
4,11: Ar = 2-benzoxazole
5,12: Ar = 4-CF3Ph
6,13: Ar = 3-NO2Ph
7,14: Ar = 2-NO2,4-COOM
8,15: Ar = 2-NO2,4-COOH
a
Scheme 1. Synthesis of compounds 9a–e, 10, 11a–c, 10, 11e, 12, 13a–e, 14a–c, 14e, 15a–
LiOH, H2O, THF, o.n., R.T., yield 10.3–93.8%.3.2. Chemistry
A common synthetic pathway was followed for the synthesis of
new small families of compounds. These structures share the five
types of secondary alicyclic amines, but are differentiated from
each other by the aromatic moiety defined by the six selected frag-
ments. Final compounds 8–13a–c, e were prepared in a one-pot
reaction using an equimolar ratio of the appropriate alicyclic sec-
ondary amine (1a–c, e) and carbon disulfide, which were stirred
at 0 C for 30 min in the presence of sodium methoxide, in order
to obtain the formation of the dithiocarbamate salt. The different
aryl chloride or bromide 2–7 was successively added in order to
get the final compounds through displacement of the chloride or
bromide leaving group by the dithiocarbamate salt (Scheme 1).
Compounds 8, 11–12d were obtained by partially changing the
reaction conditions already described, through the addition of 0.5
equivalents of carbon disulfide to piperazine in order to prevent
a double nucleophilic attachment on the two free amino groups.
Starting materials 3, 4 and 7 were not commercially available
and were synthesized according to reported procedures (Vlahakis
et al., 2013; Soares et al., 2010; Lopes et al., 2011). Compounds
15a–c, e were prepared by a base-catalyzed hydrolysis with
lithium hydroxide of the correspondent methyl ester derivatives
14a–c, e.
3.3. Biology
The newly synthesized compounds were then evaluated for
their antiviral activity in an in vitro cell-based assay, in which
HEp-2 cells were infected with luciferase-expressing RSV (Hotard
et al., 2012) in the presence of the compounds. The luciferase
expression driven by RSV is a measure for virus replication. Cells
were treated with different dilutions (30–0.5 lM) of RSV inhibitors
30 min prior to and during infection with RSV. As a control in our
assay, cells were treated with DMSO, which was used to prepare
the inhibitor stock solutions. Twenty-four hours post infection,
the luciferase activity was measured and the number of viable cells
were determined. The compound concentrations that gave 50%
reduction of RSV-driven luciferase activity (IC50) or cell viability
(CC50) compared to the DMSO control were determined by extrap-
olation. The reference compound AT-2 was tested in our RSV assay
at several dilutions (10,000–0.5 lM). Previously, Boukhvalova et al.le
e-Ph
-Ph
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X
S
S Ar
9a-e, 10,11a-c,e 12,13a-e, 14a-c,e
14a-e
15a-e
b
e. Reagents and conditions: (a) CS2, NaOMe, DMF, 300 , 0 C to R.T., yield 10–75%; (b)
Fig. 4. Chemical structures of aldrithiol (AT-2) and 10e.
Table 1
IC50 and CC50 values of the new compounds.
Compound IC50 (lM)a CC50 (lM)a SIc
AT-2b 841 733 0.9
9a 20 130 6.5
9b 47 NI >0.6
9c 56 NI >0.5
9d NI NI –
9e 18 29 1.6
10a NI NI –
10b NI NI –
10c NI 102 –
10e 6 NI >5
11a 39 NI >0.8
11b NI NI –
11c NI NI –
11e 36 123 3.4
12a 25 95 3.8
12b 43 133 3.1
12c 19 78 4.1
12d NI NI –
12e 31 NI >1
13a 43 130 3
13b 20 27 1.35
13c 27 36 1.3
13e 26 160 6.2
14a 155 NI >0.2
14b 42 NI >0.7
14c 90 NI >0.3
14e 27 NI >1.1
15a 36 NI >0.8
15b NI NI –
15c NI NI –
15e 89 NI >0.3
a NI indicates no significant inhibition at concentration >30 lM.
b Different dilutions of AT-2 (10,000–0.5 lM) were tested.
c SI = CC50/IC50.
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tion in the presence of 10 mM AT-2. In their study, the compound
was removed prior to analyzing the remaining RSV infectivity
(Boukhvalova et al., 2010). In our experimental setup the inhibition
of RSV replication in the presence of this compound can be par-
tially attributed to the cytotoxic effect of this compound (see
Table 1).
Of the compounds tested, six derivatives exhibited promising
antiviral activity with low or moderate micromolar IC50 values.
Compared to the reference compound AT-2, the activity was signif-
icantly improved. Compounds 9a and 12a, having in common a
piperidine moiety, showed a similar antiviral effect with IC50
values in the 20 lM range. Higher activity concentrations were
observed for derivatives 11a, 13a and 15a, bearing the same
alicyclic amine, and loss of antiviral activity was noted for
compounds 10a and 14a. Most of the compounds having theN-methyl piperazine substituent were associated with a dramatic
loss of antiviral activity, except for compound 12c, which showed
an IC50 of 19 lM and compound 13c, for which a toxic effect on
the cells was observed. The morpholine moiety was also less toler-
ated, with derivatives 10b, 11b and 15b having no viral inhibition
and compounds 9b, 12b and 14b being active at concentrations in
the 40 lM range. A low selectivity index (which is the ratio
CC50/IC50) was reported for compound 13b, which has cytotoxic
effects on the cells. Among the active scaffolds, compound 10e
exhibited the best potency with an IC50 of 6 lM, without apprecia-
ble effect on cell viability. Interestingly, derivatives 13e and 14e,
sharing the same benzyl piperazine moiety as 10e, were found to
be active with higher IC50 values. Reduced activity was observed
for derivatives 11e, 12e, also belonging to the same family of
benzyl piperazine compounds, while compound 9e exhibited
cytotoxicity. Results obtained so far suggest that a hydrophobic
alicyclic amine is crucial for antiviral activity. The most active
derivatives were characterized by a benzyl piperazine or piper-
azine rings. Regarding the aromatic substituent, the best results
are found for the benzoimidazole (9a), benzothiazole (10e), the
4-(trifluoromethyl)benzyl bromide (12a), 3-nitrobenzyl bromide
(13e) and methyl 4-bromomethyl-3-nitrobenzoate (14e), while
the least successful modification for this part of the structure
was the 4-bromomethyl-3-nitrobenzoic acid system, apart from
compound 15a, for which some activity retention was observed.4. Conclusion
In this study, a computer-aided approach guided the design and
synthesis of a series of zinc-reacting compounds as potential inhi-
bitors of the RSV replication. This study was based on a recent
paper that demonstrated inactivation of RSV by 10 mM AT-2, a
zinc-ejecting compound, presumably by modification of the M2-1
protein (Boukhvalova et al., 2010). Using seven selected small
fragments as building blocks for the design of new scaffolds, 30
derivatives were prepared. Their chemical structure is defined by
a common dithiocarbamate central linker, while an alicyclic sec-
ondary amine and an aromatic substituent are on the two lateral
parts. Among them, six compounds inhibited the viral replication
at low or moderate micromolar concentrations in a cell-based
assay. The most active compound, 10e, exhibited an IC50 of 6 lM,
which represents a considerable improvement compared to AT-2
(IC50 of 841 lM in our RSV inhibitory assay), a previously reported
inhibitor (Fig. 4). Common features among the active compounds
suggest the importance of the benzyl piperazine moiety on one
side of the scaffold. Although further studies are required to prove
the mechanism of action of these compounds, these results repre-
sent a very promising starting point for the development of a novel
class of RSV inhibitors.
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